60 Degrees Pharmaceuticals Implements 1-for-4 Reverse Stock Split to Maintain Nasdaq Listing
SXTP sits 68% above its 52-week low of $1.36 on elevated volume (7.6× avg).
Summary
60 Degrees Pharmaceuticals, Inc. has implemented a 1-for-4 reverse stock split, effective January 20, 2026, primarily to regain compliance with Nasdaq's minimum bid price requirement.
Key Events · Corporate Governance and Compliance · SXTP
-
Reverse Stock Split Effective
A 1-for-4 reverse stock split became effective on January 20, 2026, at 12:01 a.m. Eastern Time.
-
Nasdaq Compliance Driver
The primary purpose of the reverse stock split is to bring the company into compliance with Nasdaq's minimum bid price requirement for continued listing.
-
Share Count Reduction
The split will reduce the number of issued and outstanding common shares from approximately 5.15 million to 1.29 million.
-
Fractional Share Treatment
No fractional shares will be issued; any fractional amounts will be rounded up to one whole share.
Analysis · SXTP · Life Sciences
60 Degrees Pharmaceuticals, Inc. has executed a 1-for-4 reverse stock split, a critical move primarily aimed at regaining compliance with Nasdaq's minimum bid price requirement. While this action addresses an immediate delisting threat, reverse stock splits are generally viewed negatively by the market as they often signal a company's struggle with sustained low stock prices. Investors should monitor whether the company can maintain its listing and demonstrate fundamental business improvements to support the higher per-share price, as the split itself does not alter the company's underlying valuation or operational challenges.
At the time of this filing, SXTP was trading at $2.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $1.36 to $24.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.